Abstract
68Ga-DOTATATE PET/CT provides information of the location(s) of somatostatin receptor expressing tumors. Integrating this imaging data effectively in patient care requires the clinical history, the histopathology and biomarker information as well as grade, stage and prior imaging. Previous therapies and technical aspects of the study should be considered, given their ability to alter the interpretation of the images. This includes physiologic biodistribution of the radiotracer, as well as conditions that engender false positive results. This CME document provides a guide to the performance and interpretation of 68Ga-DOTATATE PET/CT and describes its role in the diagnostic algorithm of neuroendocrine neoplasms (NEN) and is overall utility in their management.
- Endocrine
- Neuroendocrine
- Oncology: Endocrine
- Peptides
- PET/CT
- 68Ga-DOTATATE
- Biodistribution
- Interpretation
- Molecular strategies
- PET/CT
- Copyright © 2017 by the Society of Nuclear Medicine and Molecular Imaging, Inc.